文献速递冠心病

二十碳五烯酸乙酯对心肌梗死的心脏代谢与脂质组学保护作用

Eicosapentaenoic acid ethyl ester, cardiac metabolomic and lipidomic signatures, and cardioprotection in myocardial infarction.
PubMed 文献 · Eur Heart J · 2026-01-01

本研究在高甘油三酯血症雄性大鼠中给予高剂量EPA-E或安慰剂2周后诱导心肌梗死,评估其对梗死面积和代谢组学的影响。结果显示EPA-E治疗组梗死面积更小,心梗相关死亡率有降低趋势,且心脏代谢与脂质组学特征改善,这些保护作用独立于循环甘油三酯的降低。

要点

  • EPA-E可减小高甘油三酯血症大鼠心肌梗死面积。
  • EPA-E的心脏保护作用不依赖于循环TG水平降低。
  • EPA-E改善梗死心脏的代谢组学和脂质组学特征。

核心结论

  • EPA-E治疗对心肌梗死具有直接心脏保护作用,并改善心脏代谢与脂质组学特征,不依赖于其循环TG降低效应。

研究设计与样本

  • 雄性大鼠通过高蔗糖饮食诱导高甘油三酯血症,分为HTG+EPA-E组(n=21)、HTG组(n=27)和对照饮食组(n=15)。
  • 干预2周后通过短暂冠状动脉结扎诱导心肌梗死,24小时后处死进行梗死面积、分子、组织学和组学分析,并行超声心动图检查。

主要发现

  • HTG+EPA-E组循环TG水平低于HTG组,心功能优于HTG组。
  • HTG+EPA-E组梗死面积小于HTG组和对照组(P<0.05 vs both groups)。
  • MI相关死亡率在EPA-E治疗组为29%,HTG组为56%(P=0.07)。
  • 循环TG水平与MI相关梗死面积或死亡率无相关性。
  • EPA-E治疗与梗死心脏中TG相关心脏脂毒性、凋亡、纤维化、氧化应激、促炎细胞募集和线粒体功能障碍减少相关。

关键数值与推荐

  • 高甘油三酯血症定义为高蔗糖饮食诱导后>175 mg·dL-1(基线)。
  • EPA-E治疗组MI相关死亡率为29%,HTG组为56%(P=0.07)。
  • HTG+EPA-E组梗死面积小于HTG组和CD组(P<0.05 vs both groups)。

临床怎么用

  • 在心肌梗死合并高甘油三酯血症时,EPA-E可能提供独立于降TG的心脏保护益处。
  • 临床决策中可考虑EPA-E用于改善心脏代谢和脂质组学特征,但需进一步临床验证。

局限性

  • 本研究为动物实验,结果不能直接外推到人类。
  • MI相关死亡率差异的P值为0.07,未达到统计学显著性。
  • 样本量有限,各组 n 分别为21、27和15。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The cardiovascular benefits of eicosapentaenoic acid ethyl ester (EPA-E) in MACE reduction might extend beyond its triglyceride (TG)-lowering effects. However, the mechanism behind remains unknown. This study investigated whether EPA-E exerts cardioprotection in the setting of myocardial infarction (MI). METHODS: Hypertriglyceridaemia (HTG) was induced in male rats by a high-sucrose diet (>175 mg·dL-1; baseline). Hypertriglyceridaemia rats were administered for 2 weeks high-dose EPA-E supplementation (HTG + EPA-E; n = 21) or placebo (HTG; n = 27) in combination with the diet. A control diet group (CD; n = 15) was included. After 2 weeks, MI was induced by transient coronary ligation and animals were sacrificed 24 h thereafter for infarct size, molecular, histological, and -omic analyses. Echocardiography was performed. RESULTS: HTG + EPA-E animals displayed lower circulating TG levels and better cardiac function as compared to HTG group. HTG + EPA-E animals showed smaller infarcts (P < 0.05 vs both groups), and MI-related mortality was 29% in EPA-E-treated animals (reaching levels comparable to those of the CD group), whereas it was 56% in HTG animals (P = 0.07). No correlation was observed between circulating TG levels and MI-related infarct size or mortality. Cardiac function was similarly deteriorated in all animals post-MI. Eicosapentaenoic acid ethyl ester treatment was associated with lower TG-related cardiolipotoxicity, apoptosis, fibrosis, oxidative stress, pro-inflammatory cell recruitment and less mitochondrial dysfunction in the infarcted heart. EPA-E treatment favoured a pro-resolving response and improved metabolomic and lipidomic profiles both systemically and in the infarcted heart. CONCLUSIONS: Eicosapentaenoic acid ethyl ester treatment exerts direct cardioprotective effects and ameliorates cardiac metabolic and lipidomic signatures after MI regardless of its circulating TG-lowering effects.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Alcover, Ramos-Regalado, Muñoz-García, et al. Eicosapentaenoic acid ethyl ester, cardiac metabolomic and lipidomic signatures, and cardioprotection in myocardial infarction. Eur Heart J. 2026. PMID: 41996379. doi:10.1093/eurheartj/ehag187

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。